痛风患者别嘌醇与非布司他的心脑血管风险比较:一项全国性队列研究
该研究基于韩国2002-2015年全国医保数据,纳入39 640例别嘌醇起始者与9 910例非布司他起始者(倾向评分匹配4:1)。主要复合心血管终点发生率分别为每100人年1.89与1.84,风险比1.09(95%CI 0.90, 1.32),全因死亡风险比0.96(95%CI 0.79, 1.16),均无显著差异。
要点
- 别嘌醇与非布司他起始者的主要心血管复合终点风险无显著差异。
- 全因死亡及次要心血管终点在两组间同样无显著差异。
- 高心血管风险亚组及等效剂量亚组结果与总体一致。
核心结论
- 在韩国痛风患者中,别嘌醇与非布司他起始者的非致死性心血管事件及全因死亡风险无差异。
研究设计与样本
- 基于韩国2002-2015年全国医保数据的全国性队列研究。
- 纳入39 640例别嘌醇起始者,按4:1倾向评分匹配9 910例非布司他起始者。
- 平均年龄59.1岁,男性占78.4%。
主要发现
- 主要复合心血管终点(心肌梗死、卒中/短暂性脑缺血发作或冠状动脉血运重建)发生率:别嘌醇每100人年1.89,非布司他每100人年1.84。
- 别嘌醇 vs 非布司他主要终点风险比1.09(95%CI 0.90, 1.32)。
- 全因死亡风险比0.96(95%CI 0.79, 1.16),无显著差异。
- 高心血管风险亚组及等效剂量亚组(别嘌醇≥300 mg/日 vs 非布司他≥40 mg/日)结果相似。
关键数值与推荐
- 主要复合心血管终点风险比1.09(95%CI 0.90, 1.32)。
- 全因死亡风险比0.96(95%CI 0.79, 1.16)。
临床怎么用
- 在痛风患者选择别嘌醇或非布司他时,无需因心血管风险差异而优先选择某一药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare cardiovascular (CV) risk among gout patients initiating allopurinol vs febuxostat. METHODS: Using 2002-2015 Korean National Health Insurance Service data for the entire Korean population, we conducted a cohort study on gout patients initiating allopurinol or febuxostat. The primary outcome was a composite CV end point of myocardial infarction, stroke/transient ischaemic attack, or coronary revascularization. Secondary outcomes were individual components of the primary outcome, and all-cause mortality. We used propensity score-matching with a 4:1 ratio for allopurinol and febuxostat initiators to control for confounding. Competing risk analyses were done for non-fatal outcomes accounting for deaths. RESULTS: We included 39 640 allopurinol initiators propensity score-matched on 9910 febuxostat initiators. The mean age was 59.1 years and 78.4% were male. The incidence rate per 100 person-years for the primary outcome was 1.89 for allopurinol and 1.84 for febuxostat initiators. The corresponding hazard ratio comparing allopurinol vs febuxostat initiators was 1.09 (95% CI: 0.90, 1.32). No significant difference was found for the secondary outcomes, including all-cause mortality (hazard ratio 0.96; 95% CI: 0.79, 1.16). Subgroup analyses limited to those at high CV risk and to equipotent-dose initiators (i.e. allopurinol ⩾300 mg/day vs febuxostat ⩾40 mg/day) showed similar results. CONCLUSION: Overall, this large Korean population-based study suggests no difference in the risk of non-fatal CV events and all-cause mortality between allopurinol and febuxostat initiators. These findings are consistent with the recent US Medicare population study, although the current study population consisted of younger Asians.
引用
- Kang EH, Choi HK, Shin A, et al. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. Rheumatology (Oxford). 2019. PMID: 31098635. doi:10.1093/rheumatology/kez189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。